

# **British Journal of Pharmacology**

## **Proceedings Supplement**

Proceedings of the British Pharmacological Society Meeting

6th–8th September 2000

**University of Bradford**

The *British Journal of Pharmacology* is published by Nature Publishing Group, a division of Macmillan Publishers Ltd. It is the official publication of the British Pharmacological Society.

**Scope** The *British Journal of Pharmacology* publishes 3 volumes of 8 issues per year and is published twice a month. It welcomes contributions in all fields of experimental pharmacology including neuroscience, biochemical, cellular and molecular pharmacology. The Board of Editors represents a wide range of expertise and ensures that well-presented work is published as promptly as possible, consistent with maintaining the overall quality of the journal.

This journal is covered by Current Contents, EMBASE/Excerpta Medica, BIOSIS, Elsevier Biobase/Current Awareness in Biological Sciences, CINAHL and Index Medicus.

**Editorial** Manuscripts (plus three original copies) and all editorial correspondence should be sent to: The Editorial Office, British Journal of Pharmacology, BPS Office, 16 Angel Gate, 326 City Road, London EC1V 2SG, UK. Tel: +44 207417 0432; Fax: +44 2077417 0430.

**Advertisements** Enquiries concerning advertisements should be addressed to: Robert Sloan, Advertisement Manager, 84 Arncliffe Grove, Southgate, London N14 7AR, UK. Tel: +44 208882 7199; Fax: +44 208882 7299.

**Publisher** All business correspondence, supplement enquiries and reprint requests should be addressed to *British Journal of Pharmacology*, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 1256 329242; Fax: +44 1256 810526. Publishing Manager: Sue Deeley. Production Controller: Jane Torr.

**WWW** The *British Journal of Pharmacology* is on the internet at: <http://www.bjpharmacol.org/>

The journals' home pages contain a range of information free to all readers. This includes: Editors' Details, Aims and Scope, Instructions to Authors, Subscription Prices, Reprint Ordering, Sample Copy Ordering and News, together with the contact names of our Publishing, Production, Marketing and Advertising Departments.

Readers can view Tables of Contents and Abstracts to all articles since 1997. Register now to have the Tables of Contents sent to you as each issue is published. Subscribers to the 2000 on-line version of the journal have access to PDF and HTML files with the full text of all articles published since 1997.

**Subscriptions – 2000 Subscription Rates – *British Journal of Pharmacology***  
**Institutional Subscriptions** Print (Hard Copy): EU £960, Rest of World (surface mail) £1060/US\$1664, Rest of World (airmail) £1272/US\$1997.

**Electronic – Online only** £960/US\$1507.

**Combined – Electronic Online & Print** EU £1056, Rest of World (surface mail) £1166/US\$1831, Rest of World (airmail) £1378/US\$2164.

**Personal Subscriptions (USA only)**

Print (Hard Copy) surface mail \$295; air mail \$628

**Electronic – Online only** \$295

**Combined – Electronic Online & Print**

Surface mail \$325; airmail \$384

#### **Subscriptions – Outside the USA**

Orders must be accompanied by remittance. Cheques should be made payable to Macmillan Journals Subscriptions Ltd and sent to: The Subscription Department, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Where appropriate, subscribers may make payments into UK Post Office Giro Account No: 519 2455. Full details must accompany the payment.

#### **Subscriptions – USA**

USA subscribers can call toll free: 1 800 747 3187. Please send check/money order/credit card details to: The Subscription Department, Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Prices are set in UK Sterling. Dollar prices are converted from UK Sterling at the current exchange rate. Accordingly, your credit card charge may vary slightly from the Dollar rate shown. To obtain the exact Dollar rate shown, please remit by check. All prices, specifications and details are subject to change without prior notification.

*British Journal of Pharmacology* (ISSN 0007–1188) is published twice a month by Nature Publishing Group, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA. Subscription price for institutions is \$1664 per annum (surface). Periodicals postage is paid at Rahway NJ. Postmaster: send address corrections to *British Journal of Pharmacology*, Nature Publishing Group, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001.

**Reprints** of any article in this journal are available from Nature Publishing Group, Houndmills, Basingstoke, Hampshire RG21 6XS, UK. Tel: +44 1256 329242; Fax: +44 1256 810526.

**Copyright** © 2000 Macmillan Publishers Ltd

ISSN 0007–1188

All rights of reproduction are reserved in respect of all papers, articles, illustrations, etc., published in this journal in all countries of the world.

All material published in this journal is protected by copyright, which covers exclusive rights to reproduce and distribute the material. No material published in this journal may be reproduced or stored on microfilm or in electronic, optical or magnetic form without the written authorisation of the Publisher.

Authorisation to photocopy items for internal or personal use of specific clients, is granted by Nature Publishing Group for libraries and other users registered with the Copyright Clearance Center (CCC) Transaction Reporting Service, provided that the base fee of \$15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Danvers, MA 01923, USA. 0007–1188/00 \$15.00 + \$0.00.

Apart from any fair dealing for the purposes of research or private study, or criticism or review, as permitted under the Copyright, Designs and Patent Act 1988, this publication may be reproduced, stored or transmitted, in any form or by any means, only with the prior permission in writing of the publishers, or in the case of reprographic reproduction, in accordance with the terms of licences issued by the Copyright Licensing Agency.

# INDEX TO PROCEEDINGS SUPPLEMENT

## University of Bradford

### Proceedings of the British Pharmacological Society Meeting 6th–8th September, 2000

#### Author Index

- Abbas F, Clayton J, Duckworth N, Grady A, Marshall K & Senior J, A preliminary study of the role of cGMP in human isolated myometrium from pregnant donors, 215P
- Allen AR *see* Bell D, 181P
- Anderson IK *see* Varley PG, 218P
- Andrews N, Loomis S, Oles R, Singh L & McKnight AT, Effect of pregabalin on the development of conditioned place preference (CPP) to morphine and the effect of morphine to increase accumbal dopamine in the rat, 160P
- Andrews N, Loomis S, Singh L & McKnight AT, Effect of pregabalin on maintenance of conditioned place preference (CPP) to morphine in the rat, 209P
- Asghar AUT, Bird GC & King AE, Glutamate transporters and modulation of primary afferent-mediated synaptic transmission in spinal dorsal horn neurones from normal and arthritic rats *in vitro*, 156P
- Ayman S, Fernandes F & Gibson A, Barium can distinguish between contractions of smooth muscle mediated via store-operated and voltage-operated calcium entry, 212P
- Ayman S, Wallace P, Gibson A & McFadzean I, NO inhibits carbachol- and thapsigargin-induced contraction of  $\beta$ -escin-permeabilised smooth muscle, 211P
- Babbs AJ *see* Hirst WD, 190P
- Badie-Mahdavi H *see* Worsley MA, 157P
- Barnes NM, Brady CA, Dawlaty S, McMullen AJ, Lin L, Williams JM & Hope AG, The 5-HT<sub>3</sub> receptor: one receptor, two subunits, many functions, 237P
- Barrand MA *see* Klokouzas A, 161P
- Battaglia G *see* Bruno V, 227P
- Battu GR, Zeitlin IJ & Gray AI, Anti-inflammatory activity of myeloperoxidase inhibitory molecules isolated from resin extracts of *Commiphora kua*, 187P
- Bell D, Allen RA & McDermott BJ, Altered responsiveness to  $\beta_2$ -adrenoceptor and NPY Y<sub>1</sub> receptor stimulation during progression of cardiomyocyte hypertrophy, 181P
- Bell D *see* Cullen JP, 182P
- Bennett T *see* Gardiner SM, 177P
- Bennett T *see* Liu B, 172P
- Benwell KR *see* Randall VA, 185P
- Besong G *see* Bruno V, 227P
- Beveridge TJR, Mazumdar A, Sprakes ME, Pei Q, Zetterstrom TSC & Elliott JM, Induction of Arc mRNA expression by 3,4-methylenedioxy-methamphetamine (MDMA) in the brain of the dark agouti rat, 205P
- Bickerdike MJ *see* Kennett GA, 236P
- Bird GC *see* Asghar AUR, 156P
- Bottrill FE *see* White R, 176P
- Bowers KC *see* Fagura MS, 188P
- Bowers KC *see* Theaker J, 189P
- Bowery NG *see* Chesnoy-Marchais D, 155P
- Brady CA *see* Barnes NM, 237P
- Brandi ML *see* Mancini L, 171P
- Britland S *see* Sutherland J, 221P
- Britland ST *see* Yeung CK, 217P
- Bromidge SM *see* Hirst WD, 190P
- Brown RE & Corder R, Comparison of the effects on adenosine metabolism by cultured endothelial cells of inhibitors of adenosine deaminase and nucleoside transport, 186P
- Brownhill V, Cheetham S, Kenny B & Wenham D, Characterisation of [<sup>3</sup>H]-SHU 9119 binding to human MC<sub>3</sub> and MC<sub>4</sub> melanocortin receptors, 198P
- Bruno V, Battaglia G, Storto M, D'Onofrio M, Ngomba R, Besong G, Cuomo L, De Blasi A, Catania MV, Copani A & Nicoletti F, Metabotropic glutamate receptor subtypes influence neuronal degeneration through different mechanisms, 227P
- Carollo M, Christie MI & Perretti M, Expression of MIP-2, KC and MCR-1 and their receptors in chronic granulomatous inflammation, 168P
- Catania MV *see* Bruno V, 227P
- Cathala L *see* Chesnoy-Marchais D, 155P
- Chan WM, Welch W & Sitsapesan R, Investigating the effects of adenine nucleotides and related compounds on cardiac ryanodine receptor activation using [<sup>3</sup>H]-ryanodine binding, 183P
- Charlett A, Weller C, Oxlade N, Dobbs SM & Dobbs RJ, Systemic cortisol response to *Helicobacter pylori* vacuolating toxin in idiopathic Parkinsonism and controls, 220P
- Chazot PL *see* Hann V, 197P
- Cheetham S *see* Brownhill V, 198P
- Cheetham SC *see* Mann K, 199P
- Chesnoy-Marchais D & Cathala L, Modulation of glycine receptors by dihydropyridines in rat spinal neurones, 155P
- Chootip K, Kennedy C & Gurney A, Characterisation of P2 receptors mediating contraction of the rat isolated pulmonary vasculature, 167P

- Christie MI *see* Carollo M, 168P  
 Clark BP *see* Miller JC, 202P  
 Clayton J *see* Abbas F, 215P  
 Clayton JK *see* Duckworth N, 216P  
 Colado MI *see* Mechan AO, 153P  
 Collingridge G, Glutamate receptors and synaptic plasticity, 222P  
 Conway SJ *see* Miller JC, 202P  
 Copani A *see* Bruno V, 227P  
 Corder R *see* Brown RE, 186P  
 Corder R *see* Douthwaite JA, 166P  
 Costall B *see* Sutherland J, 221P  
 Costall B *see* Yeung CK, 217P  
 Costello RW *see* Kingham PJ, 169P  
 Costello RW *see* Sawatzky DA, 170P  
 Court E *see* Kingham PJ, 169P  
 Cowburn RC *see* Plant LD, 200P  
 Crockett TR, McBride M, Ness KF, Kane KA & Wainwright CL, The effect of S6c on platelet aggregation and leukocyte free radical generation in rat blood *in vitro* and *ex vivo*, 162P  
 Crockett TR, Scott GA, McGowan NWA, Kane KA & Wainwright CL, Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721, 178P  
 Cross AJ *see* Green AR, 203P  
 Cross AJ *see* Nelson RM, 204P  
 Croucher MJ *see* Randall VA, 185P  
 Cullen JP, Bell D, Kelso EJ & McDermott BJ, Evidence for involvement of ET<sub>B</sub> receptors and associated involvement of PKC-dependent mechanisms in endothelin-1 mediated cardiomyocyte hypertrophy, 182P  
 Cunnane TC *see* Imaeda K, 214P  
 Cuomo L *see* Bruno V, 227P
- Danbolt NC, Cellular and subcellular distribution of glutamate transporters: physiological and pathophysiological implications, 223P  
 Dawlaty S *see* Barnes NM, 237P  
 Dawson NJ & Lawson K, N<sup>G</sup>-nitro-L-arginine methyl ester attenuates the vasorelaxations to DY-9708, but not cromakalim, in rat isolated aortic rings, 175P  
 De Blasi A *see* Bruno V, 227P  
 Debens TA *see* Green AR, 203P  
 Denyer M *see* Yeung CK, 217P  
 Dobbs RJ *see* Charlett A, 220P  
 Dobbs SM *see* Charlett A, 220P  
 D'Onofrio M *see* Bruno V, 227P  
 Dougall IG *see* Fagura MS, 188P  
 Dourish CT *see* Kennett GA, 236P  
 Douthwaite JA, Lees DM & Corder R, Lipopolysaccharide increases endothelin-1 synthesis in endothelial cells without increasing preproendothelin-1 gene transcription rate, 166P
- Duckworth N *see* Abbas F, 215P  
 Duckworth NJ, Clayton JK, Senior J & Marshall K, The effect of smoking on the response to a TP-mimetic on perfused segments of the human isolated umbilical artery, 216P  
 Duty S *see* Johnston T, 201P
- Edwards S *see* Varley PG, 218P  
 Egan AC *see* Obrenovitch TP, 158P  
 Elliott JM *see* Beveridge TJR, 205P  
 Elliott JM *see* Mechan AO, 153P  
 Eseh-Sumbele P, McCurrie JR & Evans T, The contribution of nitric oxide (NO) to angiotensin II-induced tachyphylaxis in rat aorta, 173P  
 Esteban B *see* Mechan AO, 153P  
 Evans T *see* Eseh-Sumbele P, 173P  
 Exley R, Zilkhal E, Urenjak J & Obrenovitch TP, Continuous monitoring of changes in brain extracellular lactate using microdialysis coupled to enzyme-amperometric analysis, 219P
- Fagura MS, McCormick M & Bowers KC, Pyridoxal-5-phosphate is a slowly dissociating P2X<sub>1</sub> receptor antagonist, 188P  
 Fagura MS *see* Theaker J, 189P  
 Fernandes F *see* Ayman S, 212P  
 Fone KCF, The 5HT<sub>6</sub> receptor: potential CNS functions, 238P  
 Ford WR *see* Headley EL, 179P
- Gardiner SM, Kemp PA, March JE & Bennett T, Influence of the ETA-receptor antagonist, SB 234551, on haemodynamic responses to lipopolysaccharides (LPS) in conscious rats, 177P  
 Gardiner SM *see* Liu B, 172P  
 Gibson A *see* Ayman S, 211P  
 Gibson A *see* Ayman S, 212P  
 Grady A *see* Abbas F, 215P  
 Gray AI *see* Battu GR, 187P  
 Grayson B, Kelly ME & Neill JC, Isolation rearing reduces the ability of 7-OH-DPAT to attenuate responding for a food-paired conditioned stimulus in the rat, 208P  
 Green AR, Hainsworth AH, Nelson RM, Debens TA, Murray TK & Cross AJ, The sedative and anticonvulsant properties of the enantiomers of AR-A008055, GABA-mimetic compounds with neuroprotective activity, 203P  
 Green AR *see* Mechan AO, 153P  
 Green AR *see* Nelson RM, 204P  
 Gurney A *see* Chootip K, 167P
- Hagan JJ, 5-HT<sub>1</sub> receptors: pharmacology and potential therapeutic applications, 239P  
 Hainsworth AH *see* Green AR, 203P  
 Hainsworth AH *see* Nelson RM, 204P  
 Hann V, Thompson CL, Lees GL & Chazot PL, Immunological identification of the H3 histamine receptor in the adult mouse striatum, 197P  
 Hanspal IS, Magid KS, Webb DJ & Megson IL, The effect of oxidative stress on endothelium-dependent and nitric oxide donor-induced relaxation in rat aortic rings: implications for nitrate tolerance, 163P  
 Headley EL, Hiley CR & Ford WR, Angiotensin II gives concentration-dependent reductions in infarct size in rat isolated perfused hearts subjected to ischaemia/reperfusion, 179P  
 Heal DJ *see* Mann K, 199P  
 Henderson Z *see* Plant LD, 200P  
 Hiley CR *see* Headley EL, 179P  
 Hiley CR *see* White R, 176P  
 Hill AP & Sitsapesan R, Novel effects of DIDS on the gating and conductance of the sheep cardiac ryanodine receptor, 184P  
 Hirst WD, Babbs AJ, Minton JAL, Rogers DC, Moss SF, Bromidge SM, Stean T & Price GW, *Ex vivo* binding with [<sup>125</sup>I]-SB-258585 to estimate *in vivo* 5-HT<sub>2</sub> receptor occupancy by 5-HT<sub>2</sub> selective compounds and typical and atypical antipsychotics, 190P  
 Hladky SB *see* Klokouzas A, 161P  
 Hlodan R *see* Varley PG, 218P  
 Ho M & McKnight AT, *In vitro* characterisation of J-113397 at the native and recombinant rat ORL<sub>1</sub> receptor, 159P  
 Hogervorst E, The effects of hormone replacement on cognitive function in elderly women, 232P  
 Hope AG *see* Barnes NM, 237P  
 Howson PA & Jane DE, Depression of synaptic transmission in the rat spinal cord mediated via Group III metabotropic glutamate receptors is sensitive to NMDA receptor antagonists, 206P
- Imaeda K, Trout SJ & Cunnane TC, Endothelin-1-induced hyperpolarisation of smooth muscle cells in the guinea-pig lower oesophageal sphincter, 214P  
 Ingebrandt S *see* Yeung CK, 217P
- Jane DE *see* Howson PA, 206P  
 Jane DE *see* Miller JC, 202P  
 Javid FA, Muhia DK & Wood D, Inhibitory influence of electrical field stimulation on N-methyl-D-aspartate receptor-induced ileal contractions,

- 207P
- Javid FA & Naylor RJ, The effect of naloxone on adaptation to motion sickness in *Suncus murinus*, 210P
- Jenner P *see* Johnston T, 201P
- Johnston T, Jenner P & Duty S, Changes in GABA<sub>B1A</sub> and GABA<sub>B2</sub> receptor gene expression in the basal ganglia and thalamus of rats with a nigro-striatal tract lesion, 201P
- Jones JA *see* Nelson RM, 204P
- Kane KA *see* Crockett TR, 162P
- Kane KA *see* Crockett TR, 178P
- Kazerani HR, Zeitlin IJ & Wainwright CL, Release of a vasodepressant factor from the rat isolated heart: effect of myocardial ischaemia and reperfusion, 180P
- Kehr J *see* Ögren SO, 230P
- Kelly JP *see* O'Loinsigh ED, 154P
- Kelly ME *see* Grayson B, 208P
- Kelso EJ *see* Cullen JP, 182P
- Kemp PA *see* Gardiner SM, 177P
- Kennedy C *see* Chootip K, 167P
- Kennett GA, Bickerdike MJ, Vickers SP, Lightowler SL & Dourish CT, The 5-HT<sub>2C</sub> receptor, a target for panaceas, 236P
- Kenny B *see* Brownhill V, 198P
- King AE *see* Asghar AUR, 156P
- King AE *see* Worsley MA, 157P
- King T *see* Varley PG, 218P
- Kingham PJ, Court E, McLean WG & Costello RW, Nerve cell-mediated eosinophil degranulation, 169P
- Klokouzas A, Barrand MA & Hladky SB, MRP1-mediated transport of 2,4-dinitrophenyl-S-glutathione (DNP-SG) in membrane vesicles prepared from human erythrocytes and COR-L23/R lung tumour cells, 161P
- Knoll W *see* Yeung CK, 217P
- Krause M *see* Yeung CK, 217P
- Lamb H *see* Randall VA, 185P
- Lambert DG *see* Nelson RM, 204P
- Lawson K *see* Dawson NJ, 175P
- Lawson M *see* Theaker J, 189P
- Lees DM *see* Douthwaite JA, 166P
- Lees GL *see* Hann V, 197P
- Leff P *see* Theaker J, 189P
- Lightowler SP *see* Kennett GA, 236P
- Lin L *see* Barnes NM, 237P
- Liu B, Bennett T & Gardiner SM, Cardiovascular effects of anandamide and of 5-HT in the absence and presence of the 5-HT<sub>3</sub>-receptor antagonist, azasetron, in conscious rats, 172P
- Liu XH, Morris R & Williams G, The electrophysiological effects of neuropeptide Y (NPY) on lateral hypothalamus neurones *in vitro*, 196P
- Lodge D, Prospects for AMPA/kainate antagonists in stroke and pain, 226P
- Loomis S *see* Andrews N, 160P
- Loomis S *see* Andrews N, 209P
- McBride M *see* Crockett TR, 162P
- McCormick M *see* Fagura MS, 188P
- McCurrie JR *see* Eseh-Sumbele P, 173P
- McCurrie JR *see* Strati I, 174P
- McDermott BJ *see* Bell D, 181P
- McDermott BJ *see* Cullen JP, 182P
- McFadzean I *see* Ayman S, 211P
- McGowan NWA *see* Crockett TR, 178P
- MacIntyre I *see* Mancini L, 171P
- McKnight AT *see* Andrews N, 160P
- McKnight AT *see* Andrews N, 209P
- McKnight AT *see* Ho M, 159P
- McLean WG *see* Kingham PJ, 169P
- McLean WG *see* Sawatzky DA, 170P
- McMullen AJ *see* Barnes NM, 237P
- McPhaden AR *see* Miller AM, 165P
- Magid KS *see* Hanspal IS, 163P
- Mancini L, MacIntyre I, Brandi ML & Perretti M, Analysis of osteoprotegerin ligand effects on the FLG 29.1 pre-osteoclastic cell line, 171P
- Mann K, Heal DJ & Cheetham SC, Characterisation of [<sup>3</sup>H]-MTII and [<sup>3</sup>H]-SHU 9119 binding to human MC<sub>4</sub> melanocortin receptors, 199P
- March JE *see* Gardiner SM, 177P
- Marshall K *see* Abbas F, 215P
- Marshall K *see* Duckworth N, 216P
- Marshall K *see* Eseh-Sumbele P, 173P
- Marshall K *see* Strati I, 174P
- Mazumdar A *see* Beveridge TJR, 205P
- Mechan AO, Colado MI, Esteban B, Elliott JM & Green AR, Evidence against MDMA-induced hyperthermia being mediated by 5-HT release in the brain, 153P
- Megson IL *see* Hanspal IS, 163P
- Meldrum BS, Metabotropic glutamate receptors as therapeutic targets in epilepsy, 224P
- Miller AM, McPhaden AR, Wadsworth RM & Wainwright CL, Studies on the role of leukocytes and TNF $\alpha$  in neointima formation and leukocyte adhesion in a rabbit model of balloon injury, 165P
- Miller AM *see* Wainwright CL, 164P
- Miller JC, Conway SJ, Clark BP & Jane DE, Novel phenylglycine analogues as potent and selective antagonists of group II mGluRs on neonatal rat primary afferent terminals, 202P
- Minton JAL *see* Hirst WD, 190P
- Misane I *see* Ögren SO, 230P
- Morgan D, Parsons ME & Whelan CJ, Evidence for nicotinic cholinergic receptors on a monocytic cell line (THP-1), 191P
- Morris R *see* Liu XH, 196P
- Moss SF *see* Hirst WD, 190P
- Muhia DK *see* Javid FA, 207P
- Murray TK *see* Green AR, 203P
- Murray TK *see* Nelson RM, 204P
- Naylor AM *see* Wibberley A, 192P
- Naylor RJ *see* Javid FA, 210P
- Naylor RJ *see* Tuladhar BR, 213P
- Neill JC *see* Grayson B, 208P
- Nelson RM, Hainsworth AH, Lambert DG, Jones JA, Murray TK, Cross AJ & Green AR, AR-A008055, a clomethiazole analogue, is neuro-protective in a global ischaemia model *in vivo* and inhibits ischaemia-induced glutamate release *in vitro*, 204P
- Nelson RM *see* Green AR, 203P
- Ness KF *see* Crockett TR, 162P
- Newgreen DT *see* Williamson IJR, 195P
- Ngomba R *see* Bruno V, 227P
- Nicoletti F *see* Bruno V, 227P
- Nunn PA *see* Wibberley A, 192P
- Nunn PA *see* Williamson IJR, 195P
- O'Boyle KM *see* O'Loinsigh ED, 154P
- Obrenovitch TP, Egan AC & Urenjak J, Local nitric oxide inhibition alters the pattern of cortical spreading depression (CSD) induced by high extracellular K<sup>+</sup> in anaesthetised rats, 158P
- Obrenovitch TP *see* Exley R, 219P
- Offenhäusser A *see* Yeung CK, 217P
- Ögren SO, Schött PA, Kehr J, Razani H & Misane I, Galanin as a modulator of brain serotonin and acetylcholine transmission: prospects in aging and dementias, 230P
- Oles R *see* Andrews N, 160P
- O'Loinsigh ED, Kelly JP & O'Boyle KM, Co-administration of D-amphetamine alters the acute and long-term effects of 3,4-methylene-dioxymethamphetamine in rats, 154P
- Oxlade N *see* Charlett A, 220P
- Palmer AM *see* Randall VA, 185P
- Parsons ME *see* Morgan D, 191P
- Patel H *see* Randall VA, 185P
- Pauwels PJ, Diverse signalling by 5-HT receptors, 234P
- Pearson HA *see* Plant LD, 200P
- Pei Q *see* Beveridge TJR, 205P
- Pennington RA & Prince RJ, Cytisine and dihydro- $\beta$ -erythroidine selectivity at muscle nicotinic receptor complexes, 194P
- Pennington RA & Prince RJ, Determinants of epibatidine selectivity at muscle nicotinic acetylcholine receptor complexes, 193P
- Perretti M *see* Carollo M, 168P

- Perretti M *see* Mancini L, 171P
- Perry E, Cholinergic components of cognitive and neuropsychiatric features of human brain aging, 231P
- Peterson DW *see* Charlett A, 220P
- Plant LD, Henderson Z, Cowburn RC & Pearson HA, A pathological mutation in Presenilin 1 modulates Na<sup>+</sup> channel function in SH-SY5Y cells, 200P
- Porter RHP *see* Randall VA, 185P
- Price GW, 5-HT autoreceptor antagonists: the next generation of anti-depressants, 235P
- Price GW *see* Hirst WD, 190P
- Prince RJ *see* Pennington RA, 193P
- Prince RJ *see* Pennington RA, 194P
- Quinn M *see* Randall VA, 185P
- Quirion R, Memory-impaired aged rodents as relevant models: molecular and pharmacological studies, 229P
- Rabbitt P, Methodologies and results of studies of cognitive changes in old age, 228P
- Ramage AG *see* Wiberley A, 192P
- Randall VA, Quinn M, Lamb H, Revell D, Benwell KR, Croucher MJ, Palmer AM, Sheardown MJ & Porter RHP, Pharmacological characterisation of human adenosine A<sub>2B</sub> receptors co-expressed with G<sub>ai6</sub> in CHO-K1 cells, 185P
- Razani H *see* Ögren SO, 230P
- Revell D *see* Randall VA, 185P
- Roberts PJ *see* Howson PA, 206P
- Roberts PJ *see* Miller JC, 202P
- Rogawski MA, NMDA, AMPA and kainate receptor antagonists as potential antiepileptic drugs, 225P
- Rogers DC *see* Hirst WD, 190P
- Sawatzky DA, McLean WG & Costello RW, The adhesion of eosinophils to a neuronal cholinergic cell line IMR32, 170P
- Schött PA *see* Ögren SO, 230P
- Scott GA *see* Crockett TR, 178P
- Senior J *see* Abbas F, 215P
- Senior J *see* Duckworth N, 216P
- Sheardown MJ *see* Randall VA, 185P
- Siau BD *see* White R, 176P
- Singh L *see* Andrews N, 160P
- Singh L *see* Andrews N, 209P
- Sitsapesan R *see* Chan WM, 183P
- Sitsapesan R *see* Hill AP, 184P
- Sprakes ME *see* Beveridge TJR, 205P
- Sprössler C *see* Yeung CK, 217P
- Stäubli UV, Positive modulators of AMPA receptors (ampakines), 233P
- Stein T *see* Hirst WD, 190P
- Storto M *see* Bruno V, 227P
- Strati I & McCurrie JR, Effects of insulin and tyrosine kinase inhibition on isolated vascular muscle, 174P
- Sutherland J & Britland S, Enhanced proliferation and migration of primary human dermal fibroblasts induced by various growth factors: implications for dermal repair, 221P
- Theaker J, Fagura MS, Lawson M & Bowers KC, P2X<sub>7</sub>-induced pore formation in a population of THP-1 cells, 189P
- Thompson CL *see* Hann V, 197P
- Trout SJ *see* Imaeda K, 214P
- Tuladhar BR, Womack MD & Naylor RJ, Evidence for 5-HT<sub>1</sub> receptor involvement in the 5-HT-induced contraction in the mouse isolated ileum, 213P
- Uddin S *see* Varley PG, 218P
- Urenjak J *see* Exley R, 219P
- Urenjak J *see* Obrenovitch TP, 158P
- Varley PG, Hlodan R, Uddin S, King T & Edwards S, Monoclonal antibody injection without a needle, 218P
- Vickers SP *see* Kennett GA, 236P
- Wadsworth RM *see* Miller AM, 165P
- Wainwright CL, Miller AM & Work LM, NO-aspirin, but not native aspirin, reduces myocardial infarct size in anaesthetised pigs subjected to ischaemia/reperfusion, 164P
- Wainwright CL *see* Crockett TR, 162P
- Wainwright CL *see* Crockett TR, 178P
- Wainwright CL *see* Kazerani HR, 180P
- Wainwright CL *see* Miller AM, 165P
- Wallace P *see* Ayman S, 211P
- Webb DJ *see* Hanspal IS, 163P
- Welch W *see* Chan WM, 183P
- Weller C *see* Charlett A, 220P
- Wenham D *see* Brownhill V, 198P
- Whelan CJ *see* Morgan D, 191P
- White R, Siau BD, Bottrill FE & Hiley CR, Interactions between isoprenaline and levromakalim in the relaxation of rat isolated mesenteric artery, 176P
- Wiberley A, Nunn PA, Naylor AM & Ramage AG, Investigation of the role of nicotinic receptors in the female rat isolated urethra, 192P
- Williams G *see* Liu XH, 196P
- Williams JM *see* Barnes NM, 237P
- Williamson IJR, Nunn PA & Newgreen DT, An investigation of a putative BK<sub>Ca</sub> potassium channel activator using isolated rat bladder and single cell studies, 195P
- Womack MD *see* Tuladhar BR, 213P
- Wood D *see* Javid FA, 207P
- Work LM *see* Wainwright CL, 164P
- Worsley MA, Badie-Mahdavi & King AE, Protein kinase A involvement in neurokinin- and nociceptive afferent-induced slow depolarisations and fos expression in rat spinal cord dorsal horn *in vitro*, 157P
- Yeung CK, Ingebrandt S, Krause M, Sprössler C, Denyer M, Britland ST, Offenhäusser A & Knoll W Investigations into the use of miniaturised Field Effect Transistors (FETs) as a novel electro-physiological tool in pharmacological research, 217P
- Zeitlin IJ *see* Battu GR, 187P
- Zeitlin IJ *see* Kazerani HR, 180P
- Zetterstrom TSC *see* Beveridge TJR, 205P
- Zilkha E *see* Exley R, 219P

## Keyword Index

- Acetylcholine transmission 230P  
 Adaptation 210P  
 Adenine nucleotides 183P  
 Adenosine 185P, 186P  
 $\beta$ -Adrenoceptors 176P  
 $\beta_2$ -Adrenoceptors 181P  
 Ageing 230P  
 Alzheimer's disease 200P  
 AMPA antagonists 225P, 226P  
 Ampakines 233P  
 Anandamide 172P  
 Angiotensin II 179P  
 Anti-arrhythmics 178P  
 Anti-inflammatory molecules 187P  
 Antibodies 197P  
 Antipsychotics 190P  
 L-AP4 206P  
 Arrhythmias 164P  
 Arteries, mesenteric 176P  
 Arteries, pulmonary 167P  
 Arteries, umbilical, human 216P
- Barium 212P  
 Blood vessels 173P  
 Bones 171P  
 Brain ageing, human 231P  
 Brain extracellular lactate 219P  
 Brain imaging 205P  
 BzATP 188P
- Calcium entry 212P  
 cAMP 157P  
 Cardiac hypertrophy 181P, 182P  
 Cardiac myocytes 217P  
 Cell adhesion molecules 170P  
 Cell culture 221P  
 Cell motility 221P  
 Cerebral ischaemia 204P  
 cGMP 215P  
 Chemokines 168P  
 Chemokine receptors 168P  
 Cholinergic components 231P  
 Cholinergic nerves 170P  
 Cholinergic receptors 191P  
 Clomethiazole 203P  
 Cloned receptors, human 198P, 199P  
 Cognitive changes 228P  
 Cognitive function 231P, 232P  
 Cognitive gerontology 228P  
*Commiphora kua* 187P  
 Conditioned stimulus 208P
- Cytokines 165P
- Dementias 229P, 230P  
 Depression 235P  
 DIDS 184P  
 Dihydropyridines 155P  
 2,4-Dinitrophenyl-S-glutathione 161P  
 Dopamine 160P  
 Dopamine receptors 208P  
 Dorsal horn 156P  
 Drug abuse 160P, 209P  
 Drug delivery 218P
- Ecstasy 153P  
 Elderly women 232P  
 Electrical field stimulation 207P  
 Electrophysiology 178P, 200P  
 Endothelin 177P  
 Endothelin antagonists 178P  
 Endothelin ET<sub>B</sub> receptors 182P  
 Endothelin-1 214P  
 Endothelium 186P  
 Enzyme-amprometric analysis 219P  
 Eosinophils 169P, 170P  
 Epilepsy 224P, 225P  
 $\beta$ -Escin 211P
- Field-effect transistors 217P  
 Flow cytometry 189P  
 FOS 157P  
 Free radicals 162P
- GABA<sub>B</sub> 201P  
 GABA<sub>B</sub> mimetic drugs 203P, 204P  
 Gabapentinoids 160P, 209P  
 Galanin 230P  
 Gene expression 201P  
 Glucose-responsive neurones 196P  
 Glucose-sensitive neurones 196P  
 Glutamate 156P  
 Glutamate receptors 222P  
 Glutamate receptor activation 223P  
 Glutamate transporters 223P  
 Glycine receptors 155P  
 Growth factors 221P
- Helicobacter pylori* 220P  
 Histamine H<sub>3</sub> receptors 197P
- Hormone replacement 232P  
 5-HT 154P, 172P, 205P, 213P, 230P  
 5-HT autoreceptor antagonists 235P  
 5-HT receptors 234P  
 5-HT<sub>2C</sub> receptors 236P  
 5-HT<sub>3</sub> receptors 213P, 237P  
 5-HT<sub>6</sub> receptors 190P, 238P  
 5-HT<sub>7</sub> receptors 239P  
 Human isolated myometrium 215P  
 Hyperpolarisation 214P  
 Hypertension 172P  
 Hyperthermia 153P
- Ileal contractions 207P  
 Infarct size 164P  
 Inflammation 168P, 169P  
 Insulin 174P  
 Ion channels 183P, 184P  
 Isolated ileum, mouse 213P  
 Isolation rearing 208P
- J-113397 159P
- Kainate antagonists 226P  
 Kainate receptor antagonists 225P
- Langendorff heart preparation 179P  
 Lateral hypothalamus 196P  
 Leukocytes 165P  
 Levromakalim 176P  
 Ligand binding 191P, 194P  
 Lipopolysaccharides 166P, 177P  
 Localisation 197P  
 Lower oesophageal sphincter 214P
- MCPP 236P  
 MDMA 153P, 154P, 205P  
 Melanocortins 198P, 199P  
 Memory formation 233P  
 Memory-impaired rats 229P  
 Metabotropic glutamate receptors 206P, 224P  
 Metabotropic glutamate receptor subtypes 227P  
 Metic drugs 203P  
 mGluRs 202P  
 Microdialysis 219P  
 Monoclonal antibodies 218P

Motion sickness 210P  
Multidrug-resistance-associated protein  
161P  
Myocardial infarction 179P  
Myocardial ischaemia 180P  
Myometrium 215P

L-NAME 175P  
Nerves 169P  
Neuronal degeneration 227P  
Neurones 200P  
Neuroprotection 204P  
Neuropsychiatric features 231P  
Neurotoxicity 154P  
Nicotine 191P, 193P, 194P  
Nicotinic receptors 192P  
Nitrate tolerance 163P  
Nitric oxide 158P, 173P, 192P, 211P  
Nitric oxide–aspirin 164P  
NMDA 206P  
NMDA antagonists 225P  
NMDA receptors 207P  
Nociceptin 159P  
NPY Y<sub>2</sub> receptors 181P  
NS-8 195P

Opioids 209P  
ORL<sub>1</sub> 159P  
Osteoprotegerin 171P  
Osteoprotegerin ligands 171P  
Oxidative stress 163P

P2X receptors 167P  
P2X<sub>7</sub> 189P  
P2X<sub>7</sub> receptors 188P  
P2Y receptors 167P  
Pain 157P, 226P  
Parkinsonism 220P  
Parkinson's disease 201P  
Pharmacological bioassays 217P  
Phenylglycines 202P  
PKC 182P  
Plant medicines 187P  
Platelet aggregation 162P  
Potassium channels 195P  
Potassium channel openers 175P  
Preproendothelin-1 166P  
Pyridoxal-5-phosphates 188P

Radioligand binding 191P, 198P, 199P  
Receptors 185P  
Red blood cells 161P  
Reporter genes 166P  
Restenosis 165P  
Ryanodine receptors 183P, 184P

Sarafotoxin 6c 162P  
SB-234551 177P  
[<sup>125</sup>I]-SB-258585 190P  
Sedation 203P  
Sequential perfusion 180P  
Serotonin 154P, 172P, 205P, 213P, 230P  
Signal transduction 185P

Smoking 216P  
Smooth muscle 211P, 212P  
Spinal cord 202P  
Spinal neurones 155P  
Spreading depression 158P  
Strokes 158P, 226P  
Structure–function 193P, 194P  
*Suncus murinus* 210P  
Symposia 222P, 223P, 224P, 225P,  
226P, 227P, 228P, 229P, 230P, 231P,  
232P, 233P, 234P, 235P, 236P, 237P,  
238P, 239P  
Synaptic plasticity 222P  
Synthase inhibition 173P

Tachyphylaxis to angiotensin 173P  
THP-1 cells 189P  
TP-mimetics 216P  
Transporters 156P  
Tyrosine kinase inhibition 174P

Urethra 192P

Vascular muscle 174P  
Vasodepressant factors 180P  
Vasodilatation 186P  
Vasorelaxation 175P